A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Bone resorption; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 01 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Sep 2018.